Supporting the Next Generation of Drug Delivery Devices
The rapid growth of GLP-1 therapies and biologic medicines is driving unprecedented demand for autoinjectors and injector pens. As production scales from millions to hundreds of millions of devices each year, manufacturers face increasing pressure to deliver reliable performance, consistent quality, and secure long-term supply, all while meeting stringent regulatory requirements.
For device engineers, material selection extends far beyond mechanical performance. Injector housings must withstand daily handling and repeated drops, resist skin oils, lipid-based drug formulations, and common disinfectants, and mold consistently at high volumes. Once qualified, the material also becomes part of the device master record, making long-term formulation stability, biocompatibility, and change control essential throughout the product lifecycle.
NexPoint’s CYCOLOY™ HC (healthcare) PC/ABS resin is engineered to meet these demands. Combining the toughness and impact resistance of polycarbonate with the processability of ABS, the material is designed for high-volume manufacturing of autoinjector and injector pen housings without compromising performance or regulatory confidence.
Supported by NexPoint’s healthcare policy, CYCOLOY HC resin is backed by pre-assessed biocompatibility documentation, including ISO 10993 and USP Class VI, helping streamline regulatory submissions and material qualification. The material also resists the chemical exposures of daily use, helping reduce the risk of environmental stress cracking throughout the device’s lifetime.
As demand for self-administered therapies continues to grow, manufacturers need more than materials that meet specifications. They need validated material solutions supported by formulation change control, dependable global manufacturing, and technical expertise that help programs move from development to commercial production with confidence.
Key benefits of CYCOLOY HC resin for drug delivery devices
- Pre-assessed biocompatibility documentation (ISO 10993 and USP Class VI) to support regulatory submissions and device qualification.
- Excellent impact performance for devices subjected to everyday handling and drop events.
- Resistance to skin oils, lipid-based formulations, and common healthcare disinfectants.
- High-flow processing for thin-wall, high-volume molding.
- Global manufacturing support with formulation change control to help validated materials remain validated.
Interested in this solution?
Let's talk.
Americas
Europe
